TNF and rheumatoid arthritis: We identify exosomal TNF-α as a key factor to induce neural hyperexcitability, and we propose the use of the FDA-approved drug infliximab, an inhibitor of TNF-α commonly used to treat rheumatoid arthritis (76–78), as a novel agent to treat BTRE.